Immuneering Corp (IMRX)vsRevolution Medicines Inc (RVMD)
IMRX
Immuneering Corp
$3.67
-3.17%
HEALTHCARE · Cap: $243.51M
RVMD
Revolution Medicines Inc
$176.35
-2.41%
HEALTHCARE · Cap: $41.76B
Smart Verdict
WallStSmart Research — data-driven comparison
Revolution Medicines Inc generates 43419460% more annual revenue ($197.56M vs $455). RVMD leads profitability with a 0.0% profit margin vs 0.0%. IMRX earns a higher WallStSmart Score of 26/100 (F).
IMRX
Avoid26
out of 100
Grade: F
RVMD
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for IMRX.
Margin of Safety
+89.8%
Fair Value
$1883.88
Current Price
$176.35
$1707.53 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Trading at 15.9x book value
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : IMRX
The strongest argument for IMRX centers on Price/Book, Debt/Equity, Altman Z-Score.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : IMRX
The primary concerns for IMRX are EPS Growth, Market Cap, Profit Margin.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
RVMD carries more volatility with a beta of 1.43 — expect wider price swings.
RVMD is growing revenue faster at -95.2% — sustainability is the question.
IMRX generates stronger free cash flow (-17M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
IMRX scores higher overall (26/100 vs 23/100). RVMD offers better value entry with a 89.8% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Immuneering Corp
HEALTHCARE · BIOTECHNOLOGY · USA
Immuneering Corp (IMRX) is a cutting-edge biotechnology firm dedicated to advancing targeted therapeutics for cancer and other critical illnesses through its proprietary drug discovery platforms. Leveraging sophisticated bioinformatics and machine learning, the company focuses on identifying and refining drug candidates that selectively intervene in pivotal biological pathways, thereby enhancing efficacy and reducing toxicity. With a robust pipeline of novel therapies and strategic alliances, Immuneering is well-positioned to thrive in the rapidly evolving domains of personalized medicine and targeted oncology, offering significant investment opportunities for institutional investors.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?